Evidence map›Paper›PMID 32380685›Full record

ArticleJournal of clinical medicine2020

Personal Autonomy as Quality of Life Predictor for Multiple Sclerosis Patients.

Rodica Padureanu, Carmen Valeria Albu, Ionica Pirici, Radu Razvan Mititelu, Mihaela Simona Subtirelu, Razvan Aurelian Turcu-Stiolica, Harri Sintonen, Vlad Padureanu, Adina Turcu-Stiolica

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Rodica PadureanuDepartment of Biochemistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0002-3095-736X
Carmen Valeria AlbuDepartment of Neurology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Ionica PiriciDepartment of Anatomy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Radu Razvan MititeluDepartment of Biochemistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0003-2998-689X
Mihaela Simona SubtireluDepartment of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Razvan Aurelian Turcu-StiolicaTrueman Consulting, 200528 Craiova, Romania.
Harri SintonenDepartment of Public Health, University of Helsinki, 00100 Helsinki, Finland.
Vlad PadureanuDepartment of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0001-7398-5689
Adina Turcu-StiolicaDepartment of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0003-1374-276X
University of Medicine and Pharmacy of Craiova · ROUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic, severe disease, characterized by a progressive alteration in neuronal transmission, which decreases personal independence and quality of life (QoL). This study aimed to investigate the relationship between QoL and personal autonomy in patients with MS, as well as its correlation with age, educational level, and diseases severity. Twenty-six MS patients were followed-up for six months. All patients completed the 15D questionnaire two times: at T0, when they started a new treatment, and at T1 after six months of treatment. At the end point, all patients completed the Personal Autonomy Questionnaire. The average patient age was 43 years (SD = 10), and 89% of them were female. The mean severity and duration of MS were 3.5 (SD = 1.75) and 9.5 (SD = 5.1), respectively. The average QoL of MS patients at T0 was 0.66 (SD = 0.18), and that at T1 was 0.71 (SD = 0.16). The scores of patients with different types of MS, i.e., relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS), were compared. SPMS patients were older than RRMS patients (mean age 47.5 vs. 39.7 years;

Indexed as

autonomymultiple sclerosisquality of life

Identifiers

PMID32380685
PMCPMC7290289
OpenAlexW3021076539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.